Publication

Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation

van Es, S. C., Venema, C. M., Glaudemans, A. W. J. M., Lub-de Hooge, M. N., Elias, S. G., Boellaard, R., Hospers, G. A. P., Schröder, C. P. & de Vries, E. G. E., 1-Feb-2016, In : Journal of Nuclear Medicine. 57, Supplement 1, p. 96-104 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Translation of New Molecular Imaging Approaches to the Clinical Setting

    Final publisher's version, 138 KB, PDF document

    Request copy

DOI

Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 different PET tracers have been or are presently being tested. With a good rationale, after development of the tracer and proven feasibility, it is of interest to evaluate whether there is a potential meaningful role for the tracer in the clinical setting-such as in staging, in the (early) prediction of a treatment response, or in supporting drug choices. So far, only F-18-FDG PET has been incorporated into breast cancer guidelines. For proof of the clinical relevance of tracers, especially for analysis in a multicenter setting, standardization of the technology and access to the novel PET tracer are required. However, resources for PET implementation research are limited. Therefore, next to randomized studies, novel approaches are required for proving the clinical value of PET tracers with the smallest possible number of patients. The aim of this review is to describe the process of the development of PET tracers and the level of evidence needed for the use of these tracers in breast cancer. Several breast cancer trials have been performed with the PET tracers 18F-FDG, 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT), and F-18-fluoroestradiol (F-18-FES). We studied them to learn lessons for the implementation of novel tracers. After defining the gap between a good rationale for a tracer and implementation in the clinical setting, we propose solutions to fill the gap to try to bring more PET tracers to daily clinical practice.

Original languageEnglish
Pages (from-to)96-104
Number of pages9
JournalJournal of Nuclear Medicine
Volume57
Issue numberSupplement 1
Publication statusPublished - 1-Feb-2016

    Keywords

  • PET, F-18-FDG PET, F-18-FLT PET, F-18-FES PET, implementation, clinical utility, POSITRON-EMISSION-TOMOGRAPHY, METASTATIC BREAST-CANCER, F-18-FDG PET/CT, FDG-PET, ESTROGEN-RECEPTORS, NEOADJUVANT CHEMOTHERAPY, DISTANT METASTASES, EARLY PREDICTION, METABOLIC FLARE, STAGE-II

ID: 28593893